Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Thrombocytopenia, Neutropenia, Lymphopenia, Anemia

In brief

This research study will investigate the safety and effectiveness of two different dose levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine and carboplatin or gemcitabine and cisplatin prescribed to women for the treatment of ovarian cancer. This experimental drug is called TXA127 and is being tested for effectiveness to see if it will help reduce some of the side effects of the chemotherapy, primarily low blood platelet levels that lead to excess bleeding. This study also intends to test the safety of TXA127 when given as an injection under the skin on a daily basis concurrently with up to 6 cycles of the prescribed chemotherapy.

Key facts

Study ID

NCT00771810

Run by

Tarix Pharmaceuticals

People needed

34

Starts

2008-10-01

Expected to finish

2011-12-01

Last updated by the study team

2017-11-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females at least 18 years of age with ovarian carcinoma who are one of the following:
• Newly diagnosed with ovarian cancer and chemotherapy naïve, or
• Post a single previous course of chemotherapy, with a 3-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit, or
• Post two or more previous courses of chemotherapy with a 6-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit.
• Must be scheduled for a course of combination chemotherapy consisting of gemcitabine and cisplatin or gemcitabine and carboplatin to be administered in 21-day cycles
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Adequate bone marrow, renal, and hepatic functions as measured by standard chemistry and hematology blood tests
• Adequate blood coagulation parameters as measured by standard blood tests for coagulation

You may not qualify if…

• Any clinical or laboratory abnormality greater than Grade 2 toxicity (NCI criteria), with the exception of laboratory parameters specified in the inclusion criteria
• Significant unstable cardiovascular disease
• Uncontrolled high blood pressure
• Current use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II antagonists
• Evidence of metastatic disease to the bone
• Metastatic disease to the CNS requiring treatment or radiation therapy
• Uncontrolled infection(s)
• Radiation therapy or chemotherapy (except as specified in the inclusion criteria) within the previous 5 years
• Concurrent use of hematopoietic or erythropoietic agents

Where it is running

• University of Southern Alabama Mitchell Cancer Institute — Mobile, Alabama, United States
• USC - LAC Medical Center — Los Angeles, California, United States
• University of California - Irvine, Chao Family Comprehensive Cancer Center — Orange, California, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Associates in Women's Health — Wichita, Kansas, United States
• Schwartz Gynecologic Oncology, PLLC — Brightwaters, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.